Lipella Pharmaceuticals to Progress Development of Oral Graft-versus-Host-Disease Treatment Candidate

New York, March 06, 2024 - PRISM MediaWire - "Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) secures FDA Approval for Investigational New Drug (IND) Application, Advancing Clinical Testing of LP-410 for Oral Graft-Versus-Host Disease (GvHD) Treatment. Clinical Study Set to ...
IceCure's ProSense® Achieves Complete Tumor Reduction in Early-Stage Breast Cancer

New York, March 06, 2024 - PRISM MediaWire - IceCure Medical Ltd. (Nasdaq: ICCM) has disclosed novel findings from an initial, autonomous breast cancer investigation, revealing a median tumor reduction of 100% at both six and twelve months subsequent to cryoablation in w...
Quoin Pharmaceuticals Expands Rare Disease Clinical Trials to Encompass Teen Patients

New York, March 04, 2024 - PRISM MediaWire - Clinical-stage biotechnology firm Quoin Pharmaceuticals (Nasdaq: QNRX) has obtained FDA clearance to enroll subjects aged 14 years and above into its two ongoing clinical trials for QRX003. These trials are dedicated to assess...
NeuroBo Pharmaceuticals to Commence Clinical Trial Addressing Obesity

New York, March 04, 2024 - PRISM MediaWire - NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has obtained Institutional Review Board (IRB) approval to advance its Phase 1 clinical trial of DA-1726, targeting obesity treatment. Anticipated commencement of patient randomizati...
Enveric Biosciences Makes Strides in Mental Health Treatment, Witnesses 127% Surge in Shares through Out-Licensing of Compound Classes

New York, N.Y., February 29, 2024 - PRISM MediaWire - Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm specializing in the development of neuroplastogenic small-molecule therapeutics for mental health disorders, has announced the initiation of negotiations via th...
Understanding Autism Spectrum Disorder in Children: Insights and Advances in Treatment

New York, March 08, 2024 - PRISM MediaWire - Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. It affects individuals differently and can range from mild to...
Lipella Pharmaceuticals to Progress Development of Oral Graft-versus-Host-Disease Treatment Candidate

New York, March 06, 2024 - PRISM MediaWire - "Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) secures FDA Approval for Investigational New Drug (IND) Application, Advancing Clinical Testing of LP-410 for Oral Graft-Versus-Host Disease (GvHD) Treatment. Clinical Study Set to ...
IceCure's ProSense® Achieves Complete Tumor Reduction in Early-Stage Breast Cancer

New York, March 06, 2024 - PRISM MediaWire - IceCure Medical Ltd. (Nasdaq: ICCM) has disclosed novel findings from an initial, autonomous breast cancer investigation, revealing a median tumor reduction of 100% at both six and twelve months subsequent to cryoablation in w...
Quoin Pharmaceuticals Expands Rare Disease Clinical Trials to Encompass Teen Patients

New York, March 04, 2024 - PRISM MediaWire - Clinical-stage biotechnology firm Quoin Pharmaceuticals (Nasdaq: QNRX) has obtained FDA clearance to enroll subjects aged 14 years and above into its two ongoing clinical trials for QRX003. These trials are dedicated to assess...
NeuroBo Pharmaceuticals to Commence Clinical Trial Addressing Obesity

New York, March 04, 2024 - PRISM MediaWire - NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has obtained Institutional Review Board (IRB) approval to advance its Phase 1 clinical trial of DA-1726, targeting obesity treatment. Anticipated commencement of patient randomizati...
Enveric Biosciences Makes Strides in Mental Health Treatment, Witnesses 127% Surge in Shares through Out-Licensing of Compound Classes

New York, N.Y., February 29, 2024 - PRISM MediaWire - Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm specializing in the development of neuroplastogenic small-molecule therapeutics for mental health disorders, has announced the initiation of negotiations via th...